Table 1. p53 Status of 142 human tumor cell lines

Footnotes

• a: Cell lines were officially supplied by the Center of JCRB Cell Bank (G) and the affiliate institutions (A, C, D, E, F and H) or by the Cancer Cell Repository, Institute of Development, Ageing and Cancer, Tohoku University (B). A, Institute of Molecular and Cellular Biology, Okayama University Medical School; C, Kihara Institute for Biological Research, Yokohama City University; D, Radiation Effects Research Foundation; E, Institute of Medical Science, University of Tokyo; F, Hatano Research Institute, Food and Drug Safety Center; G, Cell Bank, National Institute of Health Sciences; H, Tokyo Metropolitan Institute of Gerontology.
  
• b: H & N, head and neck; TCC, transitional cell carcinoma; AD, adenocarcinoma; SCC, squamous cell carcinoma; CC, choriocarcinoma; SRC, signet ring cell carcinoma; UC, undifferentiated carcinoma; ALL, acute lymphoblastic leukemia; AML, acute myeloblastic leukemia; CML-B, chronic myeloblastic leukemia with blast crisis; ACC, adenoid cystic carcinoma; GCC, giant cell carcinoma; SCLC, small cell lung carcinoma, TC, teratocarcinoma.
  
• c: Size of PCR product of p53 cDNA in agarose gel. N, normal size; L, abnormally large size; S, abnormally small size. The band intensities were evaluated as > (stronger) or = (approximately equal) if different-sized band were present. no, no PCR product was observed.
  
• d: p53 status was scored as described in Materials and Methods. WT, wild type; mt, mutant; WT/mt, both wild type and mutant p53 were expressed; mt(loss), loss of expression.
  
• e: Data were from the indicated references if cited. The details of ts mutations found in this study are summarized in Table 3.
  
• f: not examined.